Business Context and Reporting Period
Company: MEDICINOVA INC
Filing Type: Form 8-K (Regulation FD Disclosure)
Date: March 13, 2015
Context: The Company filed a Japanese report ("Kessan Tanshin") with the Tokyo Stock Exchange containing financial results for the year ended December 31, 2014, and forward-looking forecasts for 2015. This filing supplements the Company's Annual Report on Form 10-K.
Key Financial Metrics and Guidance
The filing provides financial forecasts for the interim period ending June 30, 2015, and the full year ending December 31, 2015. Historical financial results for 2014 are referenced but not detailed in this specific text.
| Period | Revenues | Operating Loss | Net Loss | Loss Per Share (Basic & Diluted) |
|---|---|---|---|---|
| Interim (6 months ending June 30, 2015) | $0 | $5,309,000 | $5,309,000 | $0.19 |
| Full Year (ending Dec 31, 2015) | $0 | $10,943,000 | $10,943,000 | $0.40 |
Note: Loss per share calculations assume a weighted average of 27,500,000 shares. The filing does not provide specific data on cash flow, debt, or liquidity metrics for the forecasted periods.
Material Changes and Outlook
Revenue Outlook: The Company forecasts zero revenue for both the interim and full-year 2015 periods, indicating a continued focus on development without commercial product sales in the forecast horizon.
Profitability: The Company expects to incur significant operating and net losses throughout 2015, with the full-year loss projected to exceed $10.9 million.
Risks, Contingencies, and Management Commentary
- Forward-Looking Statements: The forecasts are based on management assumptions and are not audited. Actual results may differ materially due to risks beyond the Company's control.
- Key Risks: Potential delays in clinical trials, regulatory approval uncertainties, inadequate therapeutic efficacy, product liability claims, and the ability to raise sufficient capital.
- Currency Translation: Supplementary financial statements in Japanese yen were translated at a rate of 119.27 JPY to 1 USD (as of February 27, 2015).
- Disclaimer: The Company undertakes no obligation to update these forward-looking statements unless required by law.
Investor Verification Checklist
- Verify the Company's current cash reserves and burn rate to assess runway against the projected $10.9 million full-year loss.
- Review the Form 10-K for the year ended December 31, 2014, to compare actual 2014 results against the 2015 forecast assumptions.
- Monitor progress of clinical trials and regulatory submissions, as delays could materially impact the timeline and cost of development.
- Confirm the weighted average share count of 27,500,000 used in the EPS calculation against recent capital activity.